Catalyst Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CATALYST PHARMS, and what generic alternatives to CATALYST PHARMS drugs are available?
CATALYST PHARMS has four approved drugs.
There are fourteen US patents protecting CATALYST PHARMS drugs.
There are one hundred and thirty-five patent family members on CATALYST PHARMS drugs in thirty-five countries and twenty-one supplementary protection certificates in fifteen countries.
Summary for Catalyst Pharms
International Patents: | 135 |
US Patents: | 14 |
Tradenames: | 3 |
Ingredients: | 3 |
NDAs: | 4 |
Drugs and US Patents for Catalyst Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Catalyst Pharms | AGAMREE | vamorolone | SUSPENSION;ORAL | 215239-001 | Oct 26, 2023 | RX | Yes | Yes | 11,382,922 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-001 | Oct 22, 2012 | RX | Yes | No | 6,949,571 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-004 | Oct 22, 2012 | RX | Yes | No | 8,772,497 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-002 | Oct 22, 2012 | RX | Yes | No | 8,772,497 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Catalyst Pharms | AGAMREE | vamorolone | SUSPENSION;ORAL | 215239-001 | Oct 26, 2023 | RX | Yes | Yes | 11,471,471 | ⤷ Sign Up | ⤷ Sign Up | ||||
Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-001 | Oct 22, 2012 | RX | Yes | No | 8,772,497 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for CATALYST PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg | ➤ Subscribe | 2016-10-24 |
International Patents for Catalyst Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
New Zealand | 589444 | ⤷ Sign Up |
Finland | C20240018 | ⤷ Sign Up |
Japan | 2007099781 | ⤷ Sign Up |
Hungary | 1300187 | ⤷ Sign Up |
European Patent Office | 1300396 | ⤷ Sign Up |
Brazil | PI0909564 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Catalyst Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1300396 | 12C0074 | France | ⤷ Sign Up | PRODUCT NAME: PERAMPANEL, SEL DE CELUI-CI OU HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/776/001 20120723 |
1300396 | C300566 | Netherlands | ⤷ Sign Up | PRODUCT NAME: PERAMPANEL, EEN ZOUT OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/776/001 .... 016 20120723 |
1300396 | C01300396/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: PERAMPANEL; REGISTRATION NO/DATE: SWISSMEDIC 62440 14.12.2012 |
1300396 | CA 2012 00052 | Denmark | ⤷ Sign Up | |
1764361 | 173 5-2013 | Slovakia | ⤷ Sign Up | PRODUCT NAME: PERAMPANEL; NAT. REGISTRATION NO/DATE: EU/1/12/776/001 - EU/1/12/776/016 20120723; FIRST REGISTRATION: EU EU/1/12/776/001 - EU/1 /12/776/016 20120723 |
1764361 | PA2013017,C1764361 | Lithuania | ⤷ Sign Up | PRODUCT NAME: PERAMPANELUM; REGISTRATION NO/DATE: EU/1/12/776/001 - EU/1/12/776/016, 2012 07 23 EU/1/12/776/017 - EU1/12/776/023 20121029 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.